丙酚替诺福韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效及其对肝纤维化指标的影响*

doi:10.3969/j.issn.1672-5069.2024.06.006

摘要/Abstract

摘要： 目的观察丙酚替诺福韦(TAF)联合肝爽颗粒治疗慢性乙型肝炎(CHB)患者的疗效,并重点评估肝纤维化指标的变化。方法 2020年1月～2023年12月我院诊治的76例CHB患者被随机分为对照组38例和观察组38例,分别给予TAF治疗或TAF联合肝爽颗粒治疗,在治疗48周末评估疗效。采用实时荧光定量PCR法检测血清HBV DNA载量,采用化学发光免疫分析法检测血清HBeAg水平,计算肝纤维化4因子指数(FIB-4),使用瞬时弹性成像仪行肝硬度检测(LSM),采用ELISA法检测血清转化生长因子β1(TGF-β1)、基质金属蛋白酶1(MMP-1)、金属蛋白酶组织抑制因子1(TIMP-1)水平。结果在治疗48 w末,观察组血清ALT复常率为94.7%,显著高于对照组的78.9%(P<0.05);观察组胁肋胀痛、舌苔黄腻、纳呆呕恶和尿黄等中医评分分别为(0.9±0.1)分、(1.0±0.2)分、(0.9±0.1)分和(0.7±0.1)分,均显著低于对照组【分别为(1.3±0.2)分、(1.3±0.2)分、(1.2±0.2)分和(0.9±0.2)分,均P<0.05】; 观察组FIB-4、LSM、血清TGF-β1和TIMP-1水平分别为(1.8±0.3)、(7.0±0.6)kPa、(21.4±5.4)ng/mL和(119.3±19.5)ng/mL,均显著低于对照组【分别为(2.2±0.4)、(9.7±1.1)kPa、(39.1±6.1)ng/mL和(168.9±22.3)ng/mL,P<0.05】,而血清MMP-1水平为(9.8±1.2)ng/mL,显著高于对照组【(7.1±1.0)ng/mL,P<0.05】。结论应用丙酚替诺福韦联合肝爽颗粒治疗CHB患者可显著减轻中医证候评分,改善肝功能,减轻肝纤维化,值得进一步验证。

关键词: 慢性乙型肝炎, 丙酚替诺福韦, 肝爽颗粒, 肝纤维化, 转换生长因子β1, 治疗

Abstract: Objective The aim of this study was to investigate efficacy of tenofovir alafenamide fumarate (TAF) and Ganshuang granules, a herbal medicine compound, combination in the treatment of patients with chronic hepatitis B (CHB). Methods 76 patients with CHB were enrolled in our hospital between January 2020 and December 2023, and were randomly divided into control (n=38) and observation group (n=38). They were treated with TAF or TAF and herbal medicine combination for 48 weeks. Serum HBV DNA load was assayed by real-time fluorescence quantitative PCR, and serum HBeAg level was detected by chemiluminescence immunoassay. TCM syndromes scores were evaluated according to the Guidelines for the Traditional Chinese Medicine Diagnosis and Treatment of Chronic Hepatitis B (2018 Edition). Fibrosis index based on four factors (FIB-4) was obtained and liver stiffness measurement (LSM) was detected by transient elastography. Serum transforming growth factor-β1 (TGF-β), matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) levels were determined by ELISA. Results By end of 48 week treatment, ALT normalization rate in the observation group was 94.7%, much higher than 78.9%(P<0.05) in the control; scores of distending pain at hypochondrium, yellow and greasy tongue coating, poor appetite and nausea and yellow urine in the observation group were(0.9±0.1), (1.0±0.2), (0.9±0.1) and (0.7±0.1), all much lower than [(1.3±0.2), (1.3±0.2), (1.2±0.2) and (0.9±0.2), all P<0.05] in the control; FIB-4 score, LSM, serum TGF-β1 and TIMP-1 levels were (1.8±0.3), (7.0±0.6)kPa, (21.4±5.4)ng/mL and (119.3±19.5)ng/mL, all significantly lower than [(2.2±0.4), (9.7±1.1)kPa, (39.1±6.1)ng/mL and (168.9±22.3)ng/mL, respectively, P<0.05], while serum MMP-1 level was (9.8±1.2)ng/mL, significantly higher than [(7.1±1.0)ng/mL, P<0.05] in the control group. Conclusion Combination of TAF and Ganshuang granules in the treatment of patients with CHB could significantly reduce TCM syndrome scores, improve liver function and relieve liver fibrosis.

Key words: Hepatitis B, Ganshuang granules, herbal medicine, Tenofovir alafenamide fumarate, Liver fibrosis, Transforming growth factor β1, Therapy

张天挺, 许晶, 姜正伟, 嵇卉. 丙酚替诺福韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效及其对肝纤维化指标的影响^*[J]. 实用肝脏病杂志, 2024, 27(6): 820-823.

Zhang Tianting, Xu Jing, Jiang Zhengwei, et al. Improvement of liver fibrosis in patients with chronic hepatitis B after tenofovir alafenamide fumarate antiviral and herbal medicine anti-fibrotic therapy[J]. Journal of Practical Hepatology, 2024, 27(6): 820-823.

参考文献

[1] Liu Z, Lin C, Mao X, et al. Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people. Gut, 2023, 72(12):2354-2363.
[2] 王冰琼,单姗,孔媛媛,等.世界卫生组织2024年版乙型肝炎防治指南与中国指南抗病毒治疗覆盖人群的比较.中华肝脏病杂志,2024,32(6):525-531.
[3] 赵超群,蔡虹,陈高峰,等.清热化湿方治疗慢性乙型肝炎及非酒精性脂肪性肝病湿热证的多中心随机双盲安慰剂对照试验.中医杂志,2022,63(8):745-753.
[4] 郭晓玲,张耀武,李梦桃,等.恩替卡韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效研究.实用肝脏病杂志,2023,26(3):340-343.
[5] Lim SG, Baumert TF, Boni C, et al.The scientific basis of combination therapy for chronic hepatitis B functional cure. Nat Rev Gastroenterol Hepatol,2023,20(4):238-253.
[6] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3)S18-39.
[7] Terrault NA, Lok AS, Wahed AS, et al. Randomized trial of tenofovir with or without peginterferon alfa followed by protocolized treatment withdrawal in adults with chronic hepatitis B. Am J Gastroenterol, 2023,118(7):1214-1225.
[8] van Bömmel F, Stein K, Heyne R, et al.A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B. J Hepatol, 2023,78(5):926-936.
[9] 中国肝炎防治基金会中华医学会感染病学分会中华医学会肝病学分会和中国研究型医院学会肝病专业委员会.瞬时弹性成像技术诊断肝纤维化专家共识(2018年更新版).中华肝脏病杂志,2019,27(3):182-191.
[10] Sulkowski MS, Agarwal K, Ma X, et al. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection. J Hepatol, 2022, 77(5):1265-1275.
[11] 刘立,李俊义,刘春云,等.肝爽颗粒联合恩替卡韦对乙型肝炎肝硬化患者血浆D-二聚体的影响.实用医学杂志,2022,38(10):1265-1270,e1275.
[12] Cremer J, Elston R, Campbell FM, et al.B-clear phase 2b study design: Establishing the efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection. Adv Ther, 2023,40(9):4101-4110.
[13] 孔祥琳,李运伦,阚东方,等.黄芪甲苷调控动脉粥样硬化小鼠肝脏代谢组学研究.中华中医药杂志,2022,37(7):3779-3784.
[14] 张明昊,高一盈,董文霞,等.丹参多酚酸盐对肝纤维化小鼠Notch-Hes1信号通路的影响.中国临床药理学杂志,2022,38(9):949-954.
[15] 赵媛,曹耀章,李小鹏.富马酸丙酚替诺福韦联合肝爽颗粒治疗慢性乙肝肝纤维化的疗效及对患者免疫功能和炎症状态的影响.海南医学,2023,34(10):1383-1387.
[16] 曹梦珍,赵旭,郑艳芳,等.基于分子对接与实验验证的板蓝根及其活性成分抗乙型肝炎病毒作用机制研究.中草药,2023,54(7):2127-2134.
[17] Atalay R, Sayar S, Ayranci FG, et al. Does hepatic steatosis influence the virological response with chronic hepatitisB patients treated with entecavir or tenofovir disoproxil fumarate? Turk J Gastroenterol, 2022, 33(7):587-595.
[18] van Velsen LM, Sonneveld MJ, van Erpecum KJ. Is tenofovir disoproxil fumarate superior to entecavir for prevention of hepatocellular carcinoma in patients with chronic hepatitis B? Hepatobiliary Surg Nutr, 2023, 12(6):919-922.
[19] Li W, Duan X, Zhu C, et al. Hepatitis B and hepatitis C virus infection promote liver fibrogenesis through a TGF-β1-induced OCT4/Nanog pathway. J Immunol, 2022, 208(3):672-684.
[20] Sam N, Yusuf I, Idris I, et al. The level of ratio between matrix metalloproteinase-1 (MMP-1) and tissue inhibitor matrix metalloproteinase-1 (TIMP-1) after prolotherapy intervention and the functional outcome in patient with frozen shoulder: A randomized controlled trial. Medicine (Baltimore), 2023, 102(30):e34356.
[21] Terrault NA, Lok AS, Wahed AS, et al.Randomized trial of tenofovir with or without peginterferon alfa followed by protocolized treatment withdrawal in adults with chronic hepatitis B. Hepatitis B Research Network. Am J Gastroenterol, 2023, 118(7): 1214-1225.
[22] Dusheiko G, Agarwal K, Maini MK.New approaches to chronic hepatitis B. N Engl J Med, 2023,388(1):55-69.

丙酚替诺福韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效及其对肝纤维化指标的影响^*

Improvement of liver fibrosis in patients with chronic hepatitis B after tenofovir alafenamide fumarate antiviral and herbal medicine anti-fibrotic therapy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张少博, 张树庚, 刘连新. 免疫治疗肝细胞癌肝移植患者现状和前景展望^*[J]. 实用肝脏病杂志, 2024, 27(6): 801-803.
[2]	郑浩, 张树庚, 王嘉倍, 郭亚飞. 肝移植术治疗肝细胞癌患者肿瘤复发再治疗策略^*[J]. 实用肝脏病杂志, 2024, 27(6): 804-807.
[3]	朱泽斌, 张树庚, 刘连新. 靶向和免疫治疗原发性肝癌:肝移植术前降期治疗应用进展^*[J]. 实用肝脏病杂志, 2024, 27(6): 808-811.
[4]	张丽, 冯禧轩, 刘飞, 延欢欢. 丙酚替诺福韦联合PEG-IFNα-2b治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 824-827.
[5]	何振文, 徐刚, 孟华, 陈辉, 周庆坤. 艾米替诺福韦再治疗低病毒血症的慢性乙型肝炎患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 828-831.
[6]	周隽, 张忠新, 徐海燕. 可视化瞬时弹性成像与声触诊弹性成像诊断慢性乙型肝炎患者肝纤维化效能比较^*[J]. 实用肝脏病杂志, 2024, 27(6): 832-835.
[7]	朱中华, 胡均贤, 李炎. 索非布韦/达克拉韦治疗CHC患者血清血管性血友病因子和可溶性血管黏附因子1水平变化^*[J]. 实用肝脏病杂志, 2024, 27(6): 836-839.
[8]	张珂瓈, 童静, 李昌平. 接受达拉他韦和阿舒瑞韦治疗的初治基因1b型慢性丙型肝炎患者疗效评价^*[J]. 实用肝脏病杂志, 2024, 27(6): 840-843.
[9]	乔进, 赵彦, 窦志华. 半量索磷布韦联合全量达卡他韦治疗终末期肾病合并慢性丙型肝炎患者疗效和耐受性评价^*[J]. 实用肝脏病杂志, 2024, 27(6): 844-847.
[10]	陈蓉蓉, 蒋黎黎, 曹利华. 自身免疫性肝炎患者血清细胞因子水平变化及其与治疗应答的关系研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 852-855.
[11]	高宇, 杨磊, 胡光明, 孙占虎, 周涛, 肖杰. 自身免疫性肝炎患者血清巨噬细胞迁移抑制因子和白细胞介素-21水平变化及其对治疗应答的影响^*[J]. 实用肝脏病杂志, 2024, 27(6): 866-869.
[12]	武羽, 韩宇星, 徐曼曼, 焦婧然, 杨雪, 段小宛, 陈煜. DRG付费改革背景下慢加急性肝衰竭患者费用盈亏分析^*[J]. 实用肝脏病杂志, 2024, 27(6): 882-886.
[13]	唐敏, 曾理, 杨鑫荣. FibroTouch和声触诊组织量化成像参数评估血吸虫病性肝病患者肝纤维化临床研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 887-890.
[14]	马莉, 顾中盛, 李想. 内镜下套扎联合奥曲肽和埃索美拉唑治疗肝硬化并发食管静脉曲张破裂出血患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(6): 903-906.
[15]	武文华, 蔡芝芳, 李亚萍, 贾晓黎, 党双锁. 肝动脉化疗栓塞联合射频消融治疗原发性肝癌患者血清炎症因子变化及其对远期生存率的影响^*[J]. 实用肝脏病杂志, 2024, 27(6): 927-930.